Qlife Holding AB (publ) (QLIFE.ST)
SEK 2.2
(-3.51%)
SEK 2.2
(-3.51%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 39.04 Million SEK | -79.73% |
| 2022 | 192.65 Million SEK | -0.41% |
| 2021 | 193.43 Million SEK | 52.08% |
| 2020 | 127.18 Million SEK | 66.05% |
| 2019 | 76.59 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 44.92 Million SEK | 15.07% |
| 2024 Q2 | 34.95 Million SEK | -22.2% |
| 2023 Q4 | 39.04 Million SEK | -73.97% |
| 2023 Q2 | 159.64 Million SEK | -16.26% |
| 2023 FY | 39.04 Million SEK | -79.73% |
| 2023 Q1 | 190.64 Million SEK | -1.04% |
| 2023 Q3 | 150 Million SEK | -6.03% |
| 2022 Q1 | 147.4 Million SEK | -23.8% |
| 2022 FY | 192.65 Million SEK | -0.41% |
| 2022 Q2 | 205.22 Million SEK | 39.23% |
| 2022 Q3 | 201.65 Million SEK | -1.74% |
| 2022 Q4 | 192.65 Million SEK | -4.47% |
| 2021 FY | 193.43 Million SEK | 52.08% |
| 2021 Q1 | 121.43 Million SEK | -4.53% |
| 2021 Q3 | 198.11 Million SEK | -9.2% |
| 2021 Q4 | 193.43 Million SEK | -2.36% |
| 2021 Q2 | 218.19 Million SEK | 79.68% |
| 2020 Q1 | 112.94 Million SEK | 47.45% |
| 2020 Q2 | 112.47 Million SEK | -0.41% |
| 2020 FY | 127.18 Million SEK | 66.05% |
| 2020 Q4 | 127.18 Million SEK | 14.55% |
| 2020 Q3 | 111.03 Million SEK | -1.28% |
| 2019 FY | 76.59 Million SEK | 0.0% |
| 2019 Q4 | 76.59 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Acarix AB (publ) | 62.88 Million SEK | 37.908% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 98.812% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 98.812% |
| Arcoma AB | 81.96 Million SEK | 52.361% |
| Bactiguard Holding AB (publ) | 682.87 Million SEK | 94.282% |
| BICO Group AB (publ) | 10.19 Billion SEK | 99.617% |
| Boule Diagnostics AB (publ) | 755.1 Million SEK | 94.829% |
| CellaVision AB (publ) | 928.71 Million SEK | 95.796% |
| Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | 32.359% |
| Chordate Medical Holding AB (publ) | 21.95 Million SEK | -77.842% |
| C-Rad AB (publ) | 404 Million SEK | 90.335% |
| Duearity AB (publ) | 15.14 Million SEK | -157.831% |
| Dignitana AB (publ) | 44.83 Million SEK | 12.904% |
| Episurf Medical AB (publ) | 104.3 Million SEK | 62.564% |
| Getinge AB (publ) | 55.09 Billion SEK | 99.929% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | 61.958% |
| Iconovo AB (publ) | 128.07 Million SEK | 69.514% |
| Integrum AB (publ) | 164.85 Million SEK | 76.316% |
| Luxbright AB (publ) | 40.68 Million SEK | 4.032% |
| Mentice AB (publ) | 322.52 Million SEK | 87.894% |
| OssDsign AB (publ) | 356.38 Million SEK | 89.044% |
| Paxman AB (publ) | 167.12 Million SEK | 76.637% |
| Promimic AB (publ) | 92.87 Million SEK | 57.959% |
| SciBase Holding AB (publ) | 64.33 Million SEK | 39.307% |
| ScandiDos AB (publ) | 81.47 Million SEK | 52.075% |
| Sectra AB (publ) | 3.21 Billion SEK | 98.784% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | 96.15% |
| Senzime AB (publ) | 433.54 Million SEK | 90.994% |
| SpectraCure AB (publ) | 144.83 Million SEK | 73.041% |
| Stille AB | 804.89 Million SEK | 95.149% |
| Vitrolife AB (publ) | 16.39 Billion SEK | 99.762% |
| Xvivo Perfusion AB (publ) | 2.19 Billion SEK | 98.222% |